RxDoctor Payments Data

Leslie Abbott

Family · Roseburg, ORNPI 1700217064

Payments from drug & device makers

$588in general payments, 2019–2025

Across 17 payments — averaging $34.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$179
  • Lilly USA, LLC$171
  • Bayer$62
  • Otsuka America Pharmaceutical, Inc.$54
  • Edwards Lifesciences$40
  • Biocryst US Sales Co., LLC$25
  • plus $57 from 3 others

What the payments were for

  • Food & beverage$588100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$588 in reported general payments places this provider in the 75th percentile of 1,130 family providers in Oregon.

See all family providers in Oregon

Medicare billing

Part B allowed, 2024
$15,039
Medicare patients
83
Services billed
267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban11$13,603
OzempicSemaglutide14$12,943
ZenpepLipase/Protease/Amylase11$7,209
Duloxetine Hcl49$2,189
Estradiol37$1,591
Albuterol Sulfate HfaAlbuterol Sulfate37$1,557
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen72$1,219
Levothyroxine Sodium134$1,080
Pregabalin43$906
Atorvastatin Calcium64$809
Potassium Chloride55$658
Propranolol Hcl ErPropranolol Hcl13$582
Gabapentin38$501
Lisinopril83$500
Bumetanide24$464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$12,94314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,130 family providers in Oregon.

Other family in Roseburg

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →